Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (ATTRACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04944069
Recruitment Status : Not yet recruiting
First Posted : June 29, 2021
Last Update Posted : June 29, 2021
Sponsor:
Collaborator:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Second Affiliated Hospital of Nanchang University

Brief Summary:
A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.

Condition or disease Intervention/treatment Phase
NSCLC Leptomeningeal Metastasis EGFR Activating Mutation Drug: Almonertinib Drug: Bevacizumab Not Applicable

Detailed Description:
This is a prospective, open-label, multi-center, single-arm study to evaluate the efficacy and safety of Almonertinib combined with Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis. ALL patients were treated with Almonertinib 110mg oral daily and Bevacizumab 15mg/kg intravenous every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Almonertinib Combined With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis: A Prospective, Open-label, Multi-center, Single-arm Study
Estimated Study Start Date : July 2021
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Almonertinib With Bevacizumab
Almonertinib 110 mg oral once daily with Bevacizumab 15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)
Drug: Almonertinib
110 mg oral once daily

Drug: Bevacizumab
15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)




Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: From date of enrollment until the date of death, up to 2 years ]
    OS is the time from the date of enrollment until death due to any cause


Secondary Outcome Measures :
  1. Time to Symptom Resolution [ Time Frame: From baseline, then every 3 weeks, up to 2 years ]
    Time to symptom resolution is the time from first drug dosage date (C1D1) until the date of symptom resolution

  2. Progression Free Survival (PFS) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    PFS is the time from date of enrollment until the date of PD (by investigator assessment) or death

  3. Objective Response Rate (ORR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    ORR is the proportion of patients with a best overall response of complete response or partial response (CR+PR)

  4. Disease Control Rate (DCR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    DCR is the proportion of patients with a best overall response of complete response, partial response or stable disease(CR+PR+SD)

  5. Duration of Response (DoR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    DoR is the time from date of first documented response until the date of PD (by investigator assessment) or death

  6. Intracranial Progression Free Survival (iPFS) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Intracranial progression-free survival

  7. Intracranial Objective Response Rate (iORR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Intracranial objective response rate

  8. Intracranial Disease Control Rate (iDCR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Intracranial disease control rate

  9. Intracranial Duration of Response (iDoR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Intracranial duration of response

  10. Extracranial Progression Free Survival (ePFS) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Extracranial progression-free survival

  11. Extracranial Objective Response Rate (eORR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Extracranial objective response rate

  12. Extracranial Disease Control Rate (eDCR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Extracranial disease control rate

  13. Extracranial Duration of Response (eDoR) [ Time Frame: From baseline, then every 6 weeks, up to 2 years ]
    Extracranial duration of response

  14. Assess the safety of Almonertinib Combined With Bevacizumab [ Time Frame: From baseline, then every 3 weeks, up to 2 years ]
    Number of adverse events (AEs)/serious adverse events (SAEs)


Other Outcome Measures:
  1. Evaluate the correlation between the results of CSF genetic testing and drug resistance mechanisms [ Time Frame: CSF samples will be collected on Cycle 1 Day 1, Cycle 2 Day 1 and within one week after disease progression (each cycle is 21 days) ]
    Evaluate the correlation between the results of CSF genetic testing and drug resistance mechanisms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, age in 18-75 years.
  2. The Eastern Cooperative Oncology Group (ECOG) physical status score is 0-2 and has not deteriorated in the previous 2 weeks, with a minimum expected survival of 12 weeks.
  3. Histologically confirmed patients with NSCLC leptomeningeal metastasis by positive cerebrospinal fluid cytological examination.
  4. Tumor tissue samples or blood are confirmed to be EGFR sensitive mutations (including exon 19 deletion or L858R).
  5. There must be at least one measurable extracranial lesion that has not been locally treated at the time of enrollment.
  6. Females should be using adequate contraceptive measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at Screening: a) Postmenopausal defined as age more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments. b) Women under 50 years old would be considered postmenopausal if they have been amenorrheic for 12 months or more, following cessation of exogenous hormonal treatments, and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range for the laboratory. c) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not by tubal ligation.
  7. Male patients should be willing to use barrier contraception (i.e., condoms).
  8. For inclusion in study, patient must provide a written informed consent.

Exclusion Criteria:

  1. Treatment with any of the following: a) Prior treatment with systemic anti-cancer therapy for locally advancer or metastatic NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug. b) Prior treatment with an EGFR TKI. c) Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug. d) Radiotherapy with a limited field of radiation for palliation within 4 week of the first dose of study drug, with the exception of patients receiving radiation to > 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug. e) Medications that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug.
  2. Patients with other malignancies, except basal cell carcinoma and carcinoma in situ.
  3. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment, with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.
  4. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension or active bleeding diatheses, which, in the Investigator's opinion, makes it undesirable for the patient to participate in the trial OR which would jeopardize compliance with the protocol such as active infection. Screening for chronic conditions is not required..
  5. Refractory nausea, vomiting, or chronic gastrointestinal diseases, inability to swallow the study drug, or previous significant bowel resection that would preclude adequate absorption of Almonertinib.
  6. Any of the following cardiac criteria: a) Mean resting corrected QT interval (QTc) > 470 ms obtained from 3 electrocardiograms (ECGs), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF). b) Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG (e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, PR interval > 250 ms). c) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval. d) Left ventricular ejection fraction (LVEF)< 50%.
  7. Inadequate bone marrow reserve or organ function, as demonstrated by any of the following laboratory values: a) Absolute neutrophil count (ANC) <1.5×10^9 / L. b) Platelet count <100×10^9 / L. c) Hemoglobin <90 g/L (<9 g/dL). d) Alanine aminotransferase > 2.5 × upper limit of normal (ULN) if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases. e) Aspartate aminotransferase (AST) > 2.5 × ULN if no demonstrable liver metastases or > 5 × ULN in the presence of liver metastases. f) Total bilirubin (TBL) > 1.5 × ULN if no liver metastases or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases. g) Creatinine > 1.5 × ULN concurrent with creatinine clearance < 50 mL/min (measured or calculated by the Cockcroft-Gault equation); confirmation of creatinine clearance is only required when creatinine is > 1.5 × ULN. h) ALB <28 g/L.
  8. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
  9. Women who are breastfeeding or have a positive urine or serum pregnancy test at the Screening Visit.
  10. History of hypersensitivity to any active or inactive ingredient of Almonertinib, or to drugs with a similar chemical structure or class to Almonertinib.
  11. Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  12. Any severe and uncontrolled ocular disease that may, in the ophthalmologist's opinion, present a specific risk to the patient's safety.
  13. Any disease or condition that, in the opinion of the Investigator, would compromise the safety of the patient or interfere with study assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04944069


Contacts
Layout table for location contacts
Contact: Liu Anwen, PhD +8613767120022 awliu666@163.com
Contact: Huang Long, PhD +8613699549060 ndefy13211@ncu.edu.cn

Locations
Layout table for location information
China, Jiangxi
The Second Afiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Sponsors and Collaborators
Second Affiliated Hospital of Nanchang University
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Study Director: Liu Anwen, PhD Second Affiliated Hospital of Nanchang University
Publications of Results:

Layout table for additonal information
Responsible Party: Second Affiliated Hospital of Nanchang University
ClinicalTrials.gov Identifier: NCT04944069    
Other Study ID Numbers: HSM-10296-A016
First Posted: June 29, 2021    Key Record Dates
Last Update Posted: June 29, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Second Affiliated Hospital of Nanchang University:
Leptomeningeal Metastasis
Non-Small Cell Lung Cancer
EGFR Activating Mutation
Almonertinib
Bevacizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplasms
Neoplasms by Site
Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Meningeal Carcinomatosis
Neoplastic Processes
Pathologic Processes
Nervous System Diseases
Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors